Wenxin Xu

Assistant Professor of Medicine

Dana-Farber Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Wenxin Xu is an Assistant Professor of Medicine at Dana-Farber Cancer Institute in the United States. His research primarily focuses on renal cell carcinoma, with recent articles exploring prognostic markers, therapeutic strategies, and artificial intelligence applications in oncology. His work emphasizes the significance of plasma kidney injury molecule-1 as a clinical predictor and the use of AI for extracting cancer outcomes from electronic health records.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (3)

Srinivas Viswanathan

Dana-Farber Cancer Institute

UNITED STATES

View details

Bradley McGregor

Harvard University

UNITED STATES

View details

Amin Nassar

Yale University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Wenxin Xu

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma

KIM-1 as a Prognostic Marker in Renal Cell Carcinoma

Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes

Extraction and Imputation of Eastern Cooperative Oncology Group Performance Status From Unstructured Oncology Notes Using Language Models

Germline variants associated with toxicity to immune checkpoint blockade

Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Checkpoint inhibitor immunotherapy in kidney cancer

Collaborators (3)

Srinivas Viswanathan

Bradley McGregor

Amin Nassar

Make your next move.